ES2634019T3 - Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido - Google Patents

Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido Download PDF

Info

Publication number
ES2634019T3
ES2634019T3 ES14712945.6T ES14712945T ES2634019T3 ES 2634019 T3 ES2634019 T3 ES 2634019T3 ES 14712945 T ES14712945 T ES 14712945T ES 2634019 T3 ES2634019 T3 ES 2634019T3
Authority
ES
Spain
Prior art keywords
crystalline form
acetic acid
triethylamine salt
substituted thiazolyl
thiazolyl acetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14712945.6T
Other languages
English (en)
Inventor
Weijiang Zhang
Michael R. Tracey
Junning Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma Antibiotics IP LLC
Original Assignee
Theravance Biopharma Antibiotics IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics IP LLC filed Critical Theravance Biopharma Antibiotics IP LLC
Application granted granted Critical
Publication of ES2634019T3 publication Critical patent/ES2634019T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Una forma cristalina de la sal de trietilamina del ácido (2Z)-2-(2-amino-5-clorotiazol-4-il)-2-(3-N-tertbutoxicarbonilaminopropoxiimino) acético; en la que la forma cristalina se caracteriza por al menos una de las siguientes propiedades: (a) un patrón de difracción de rayos X que comprende picos de difracción a valores 2θ de 5.00±0.20, 12.92±0.20, 15.00±0.20, 16.92±0.20, 22.36±0.20, 23.36±0.20 y 24.54±0.20; (b) una temperatura de inicio de fusión de aproximadamente 139°C; o (c) parámetros cristalinos a 293 K que comprenden (i) un sistema cristalino monoclínico, (ii) un grupo espacial P21/c, y (iii) dimensiones unitarias de la celda sustancialmente igual a: a >= 8.587(4) Å, b >= 35.594(12) Å, c >= 8.308(3) Å y β >=100.63(4)°.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES14712945.6T 2013-03-13 2014-03-06 Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido Active ES2634019T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779091P 2013-03-13 2013-03-13
US201361779091P 2013-03-13
PCT/US2014/021080 WO2014164187A1 (en) 2013-03-13 2014-03-06 Crystalline form of a substituted thiazolylacetic acid triethylamine salt

Publications (1)

Publication Number Publication Date
ES2634019T3 true ES2634019T3 (es) 2017-09-26

Family

ID=50382685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14712945.6T Active ES2634019T3 (es) 2013-03-13 2014-03-06 Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido

Country Status (19)

Country Link
US (1) US9139542B2 (es)
EP (1) EP2970164B1 (es)
JP (2) JP6404309B2 (es)
KR (1) KR20150126368A (es)
CN (1) CN105121417B (es)
AU (1) AU2014249611B2 (es)
BR (1) BR112015022600A2 (es)
CA (1) CA2902724A1 (es)
EA (1) EA027911B1 (es)
ES (1) ES2634019T3 (es)
GE (1) GEP201706779B (es)
IL (1) IL240600A0 (es)
MD (1) MD4719C1 (es)
MX (1) MX351963B (es)
PH (1) PH12015502067B1 (es)
SG (1) SG11201507221VA (es)
TW (1) TWI627165B (es)
UA (1) UA115087C2 (es)
WO (1) WO2014164187A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021023784A2 (pt) * 2019-05-31 2022-01-04 Hyundai Pharm Co Ltd Forma cristalina i de um composto, método para preparar a forma cristalina i, e, composição farmacêutica para prevenir ou tratar uma doença metabólica

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
US4372952A (en) 1978-07-31 1983-02-08 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB2033377B (en) 1978-09-11 1983-05-05 Fujisawa Pharmaceuticalco Ltd Cephem compounds and processes for preparation thereof
US4341775A (en) 1978-09-11 1982-07-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4220761A (en) 1978-09-12 1980-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives
DE2945248A1 (de) 1978-11-13 1980-05-22 Fujisawa Pharmaceutical Co Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel
EP0055465B1 (en) * 1980-12-31 1989-08-23 Fujisawa Pharmaceutical Co., Ltd. 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof
JP2519054B2 (ja) 1986-06-09 1996-07-31 武田薬品工業株式会社 新規セフェム化合物
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
JPH04221388A (ja) * 1990-12-20 1992-08-11 Asahi Chem Ind Co Ltd セファロスポリン化合物およびその製造法
TWI335332B (en) 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ITMI20012363A1 (it) 2001-11-09 2003-05-09 Antibioticos Spa Metodo per la sintesi di catene laterali di cefalosporine
EP1507796B1 (en) 2002-05-24 2012-05-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
GB0416379D0 (en) 2004-07-22 2004-08-25 Sandoz Ag Organic compounds
TW200637559A (en) 2005-03-29 2006-11-01 Shionogi & Co 3-propenylcefem derivative

Also Published As

Publication number Publication date
IL240600A0 (en) 2015-09-24
EP2970164B1 (en) 2017-05-03
PH12015502067A1 (en) 2016-01-25
EA027911B1 (ru) 2017-09-29
WO2014164187A1 (en) 2014-10-09
CN105121417A (zh) 2015-12-02
MX351963B (es) 2017-11-06
JP2018197256A (ja) 2018-12-13
TW201444810A (zh) 2014-12-01
JP2016512257A (ja) 2016-04-25
PH12015502067B1 (en) 2016-01-25
BR112015022600A2 (pt) 2017-07-18
CN105121417B (zh) 2017-11-17
MD4719C1 (ro) 2021-05-31
EP2970164A1 (en) 2016-01-20
JP6404309B2 (ja) 2018-10-10
MD4719B1 (ro) 2020-10-31
AU2014249611A1 (en) 2015-09-17
EA201591708A1 (ru) 2016-01-29
TWI627165B (zh) 2018-06-21
CA2902724A1 (en) 2014-10-09
GEP201706779B (en) 2017-11-27
US20140275554A1 (en) 2014-09-18
AU2014249611B2 (en) 2017-12-21
US9139542B2 (en) 2015-09-22
MX2015012146A (es) 2015-11-25
HK1214596A1 (en) 2016-07-29
UA115087C2 (uk) 2017-09-11
KR20150126368A (ko) 2015-11-11
SG11201507221VA (en) 2015-10-29
MD20150099A2 (ro) 2016-02-29

Similar Documents

Publication Publication Date Title
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
AR122183A2 (es) Proceso para la preparación de una forma cristalina de un inhibidor de pde4, forma cristalina, composición farmacéutica para inhalación, usos y solvato
ES2656623T3 (es) Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
PE20121824A1 (es) Proceso para preparar y purificar acidos grasos
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
BR112019006066A2 (pt) método para produzir a forma cristalina de modificação a de calcobutrol
FR3001970B1 (fr) Procede de preparation d'acide 2,5-furane dicarboxylique
BR112015017051A2 (pt) método para produzir ácido acrílico
EA201591205A1 (ru) Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил)-метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры
AR092069A1 (es) Proceso para la produccion de un material de espinela
BR112016010862A8 (pt) formas mórficas de ésteres de hexadeciloxipropil-fosfonato, seu método de preparo e composição compreendendo a dita forma mórfica
FR3012290B1 (fr) Procede de preparation de sels d'acides carboxyliques herbicides
MX2017007573A (es) Composicion acuosa novedosa.
ES2634019T3 (es) Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido
CL2015002065A1 (es) Método para mejorar composiciones de sal de nitrato por medio de ácido nítrico para su uso con medio de transferencia de calor o medio de almacenamiento de calor.
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
RU2017142996A (ru) Натриевая соль ингибитора транспортера мочевой кислоты и его кристаллическая форма
BR112017010932A2 (pt) método para recuperar cristais de ácido succínico com o uso de tensoativos durante a cristalização e cristais resultantes
ES2574619T3 (es) Formación de éster de ácido graso y ácido hidroxicarboxílico
ES2525528T3 (es) Amicolamicina, método para su producción y su utilización
BR112015029745A2 (pt) método para desidratação de ácidos carboxílicos alfa-substituídos
JP2013059750A5 (es)
CU20160005A7 (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1 h-pirrol-2-il]metilen}-2-0xo-2,3-dihidro-1 h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su procedimiento de preparación, y las formulaciones que la contienen